NO942551L - Humanproteaseinhibitorvariant av Kunitz-type - Google Patents

Humanproteaseinhibitorvariant av Kunitz-type

Info

Publication number
NO942551L
NO942551L NO942551A NO942551A NO942551L NO 942551 L NO942551 L NO 942551L NO 942551 A NO942551 A NO 942551A NO 942551 A NO942551 A NO 942551A NO 942551 L NO942551 L NO 942551L
Authority
NO
Norway
Prior art keywords
amino acid
protease inhibitor
variant
type human
naturally occurring
Prior art date
Application number
NO942551A
Other languages
English (en)
Norwegian (no)
Other versions
NO942551D0 (no
Inventor
Fanny Norris
Kjeld Norris
Soeren Erik Bjoern
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942551D0 publication Critical patent/NO942551D0/no
Publication of NO942551L publication Critical patent/NO942551L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
NO942551A 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type NO942551L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200004 1992-01-07
PCT/DK1993/000003 WO1993014120A1 (en) 1992-01-07 1993-01-07 A human kunitz-type protease inhibitor variant

Publications (2)

Publication Number Publication Date
NO942551D0 NO942551D0 (no) 1994-07-06
NO942551L true NO942551L (no) 1994-09-07

Family

ID=8153774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942551A NO942551L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type

Country Status (15)

Country Link
EP (1) EP0621870B1 (hu)
JP (1) JPH07506241A (hu)
AT (1) ATE152735T1 (hu)
AU (1) AU675925B2 (hu)
CA (1) CA2127250A1 (hu)
CZ (1) CZ164594A3 (hu)
DE (1) DE69310499D1 (hu)
FI (1) FI943232A0 (hu)
HU (1) HUT70294A (hu)
IL (1) IL104326A0 (hu)
NO (1) NO942551L (hu)
NZ (1) NZ246568A (hu)
RU (1) RU94045952A (hu)
WO (1) WO1993014120A1 (hu)
ZA (1) ZA9397B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JP3805785B2 (ja) * 1994-01-11 2006-08-09 ダイアックス コープ． カリクレイン阻害クニッツドメイン蛋白質およびその相同体
JP4137997B2 (ja) 1994-01-11 2008-08-20 ダイアックス コープ． クニッツドメインから誘導されたヒトプラスミンの阻害剤
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
ATE226249T1 (de) * 1994-08-05 2002-11-15 Chiron Corp Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH11504938A (ja) * 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2709103T3 (es) 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
PT1663281E (pt) 2003-08-29 2014-03-17 Dyax Corp Inibidores de proteases poli-peguilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK1976985T3 (da) * 2005-12-29 2013-10-21 Univ California Fremgangsmåder og præparater relateret til mutant Kunitz-domæne I af TFPI-2
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
BR122021014783B1 (pt) 2008-12-19 2023-03-14 Baxalta GmbH Peptídeo que se liga a tfpi, uso do peptídeo, composição farmacêutica e método para purificação de tfpi
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101798346B (zh) * 2009-02-06 2013-05-29 复旦大学 一种酵母表达的长效重组人组织因子途径抑制物
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
CN103025345B (zh) 2010-03-19 2016-01-20 巴克斯特国际公司 Tfpi抑制剂及使用方法
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
AU2013235741C1 (en) 2012-03-21 2017-12-21 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
FI943232A (fi) 1994-07-06
AU675925B2 (en) 1997-02-27
JPH07506241A (ja) 1995-07-13
ZA9397B (en) 1993-08-10
HU9401992D0 (en) 1994-09-28
IL104326A0 (en) 1993-05-13
NZ246568A (en) 1996-02-27
EP0621870A1 (en) 1994-11-02
NO942551D0 (no) 1994-07-06
FI943232A0 (fi) 1994-07-06
AU3345893A (en) 1993-08-03
RU94045952A (ru) 1996-10-10
CA2127250A1 (en) 1993-07-22
ATE152735T1 (de) 1997-05-15
EP0621870B1 (en) 1997-05-07
DE69310499D1 (de) 1997-06-12
WO1993014120A1 (en) 1993-07-22
HUT70294A (en) 1995-09-28
CZ164594A3 (en) 1994-12-15

Similar Documents

Publication Publication Date Title
NO942551D0 (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942550D0 (no) Humanproteaseinhibitorvariant av Kunitz-type
HU9401990D0 (en) Human kunitz-type protease inhibitor variant
MX9101788A (es) Composiciones de tinta a base de agua
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
FI935172A0 (fi) Inhibitorer av katepsin G och elastas foer foerhindrande degeneration avbindvaevnad
MX9201416A (es) Peptidos y pseudopeptidos antitromboticos.
CA2043228A1 (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
EP0354820A3 (en) Novel peptide derivatives and anti-dementia agents
SE8703855D0 (sv) Vasoaktiva peptider
IT1264129B1 (it) Peptidi ad attivita' immunomodulatoria derivati da frammenti di leucochinina
KR930016980U (ko) Tv의 고압조기 방전회로
KR940021304U (ko) 고압 개폐기의 동시 투입 방지장치